Surgically Targeted Radiation Therapy (STaRT) for Brain Tumors
GT Medical Technologies announced today that it has earned the International Organization for Standardization (ISO) 13485:2016 certification from GMED. The certification demonstrates the company’s compliance with medical device quality management system requirements under the Medical Device Single Audit Program (MDSAP).
GT has a number of advantages. Unlike with traditional brachytherapy, the collagen tile provides a buffer around the radiation sources, allowing delivery of the optimal radiation dose while preserving healthy tissue.
GT Medical Technologies, Inc. announced today it was named Company of the Year for Health Products & Services in the 2022 American Business Awards. This honor acknowledges GT Medical Technologies’ pioneering technology GammaTile® Therapy, FDA-cleared for treating newly diagnosed malignant and recurrent brain tumors.
GT Medical Technologies, Inc. announced today that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA. The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy.
GT Medical Technologies Inc., creators of GammaTile Therapy, a Surgically Targeted Radiation Treatment for operable brain tumors, today announced its 2021 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2021.
A diagnosis of cancer is shocking for most people. But a diagnosis of brain cancer may carry additional fear when one considers these facts: no other cancer is as challenging to effectively treat as brain cancer, and the average five-year survival rate for people with malignant brain tumors is about 36%.
Fortunately, the availability of a novel treatment called GammaTile® Therapy is offering hope for people like 68-year-old Jane Finch Hall.
Saint Alphonsus doctors are now the first in the Northwest to use GammaTile–a radiation therapy treatment for brain tumors.
The FDA-cleared treatment surgically implants postage-stamp-sized tiles which provide radiation over the course of 33 days and then disintegrate.
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor.
Mayfield Brain & Spine’s Vincent DiNapoli, M.D., Ph.D. was the first surgeon in the eastern U.S. to perform surgery on recurrent brain tumors using a new radiation delivery technique called GammaTile Therapy. Now, he’s partnered with Oncology Hematology Care and Jewish Hospital – Mercy Health (where he’s also the director of the Brain Tumor Center) for a new study using GammaTile to treat newly diagnosed primary cancer that’s moved to the brain. DiNapoli explains how the treatment works.
Precision medicine is revolutionizing cancer treatment. Instead of using the same treatment for the same type of cancer, precision medicine tailors treatment to each individual. Precision medicine—also known as personalized medicine—takes into account someone’s genes, lifestyle and environment to find the most effective course of action for them.